Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Bausch & Lomb saves 2022's medtech IPO scene from washout as markets close for new entrants.
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.